Literature DB >> 23756473

Epidemiology of juvenile myoclonic epilepsy.

Carol S Camfield1, Pasquale Striano, Peter R Camfield.   

Abstract

Juvenile myoclonic epilepsy (JME) is a widely recognized presumed genetic, electroclinical idiopathic generalized epilepsy syndrome. The prevalence of JME in large cohorts has been estimated to be 5% to 10% of all epilepsies and around 18% of idiopathic generalized epilepsies but may be lower in some settings. There is a marked female predominance. However, some of the basic epidemiology of JME is not well known, possibly because the syndrome is not sharply defined. A questionnaire study about the diagnostic criteria for JME suggests that diagnosis of JME can be made with the history of myoclonus plus a single generalized tonic-clonic seizure plus generalized fast spike-waves or polyspike-waves on the EEG. However, until these diagnostic criteria are fully accepted, the detailed epidemiology of JME will remain imprecise.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23756473     DOI: 10.1016/j.yebeh.2012.06.024

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  34 in total

Review 1.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

2.  The developmental evolution of the seizure phenotype and cortical inhibition in mouse models of juvenile myoclonic epilepsy.

Authors:  Fazal Arain; Chengwen Zhou; Li Ding; Sahar Zaidi; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

3.  The Timing, Nature, and Range of Neurobehavioral Comorbidities in Juvenile Myoclonic Epilepsy.

Authors:  Dace N Almane; Jana E Jones; Taylor McMillan; Carl E Stafstrom; David A Hsu; Michael Seidenberg; Bruce P Hermann; Temitayo O Oyegbile
Journal:  Pediatr Neurol       Date:  2019-03-19       Impact factor: 3.372

4.  A Review of the Differences in Developmental, Psychiatric, and Medical Endophenotypes Between Males and Females with Autism Spectrum Disorder.

Authors:  Eric Rubenstein; Lisa D Wiggins; Li-Ching Lee
Journal:  J Dev Phys Disabil       Date:  2015-02

5.  Sex-specific behavioral traits in the Brd2 mouse model of juvenile myoclonic epilepsy.

Authors:  T Chachua; C Goletiani; G Maglakelidze; G Sidyelyeva; M Daniel; E Morris; J Miller; E Shang; D J Wolgemuth; D A Greenberg; J Velíšková; L Velíšek
Journal:  Genes Brain Behav       Date:  2014-08-28       Impact factor: 3.449

6.  Epidemiology and clinical manifestations of juvenile myoclonic epilepsy (JME) in Iran.

Authors:  Ali A Asadi-Pooya; Zabihollah Hashemzehi; Mehrdad Emami
Journal:  Neurol Sci       Date:  2014-12-05       Impact factor: 3.307

7.  Omitting Hyperventilation in Electroencephalogram during the COVID-19 Pandemic May Reduce Interictal Epileptiform Discharges in Patients with Juvenile Myoclonic Epilepsy.

Authors:  Keisuke Hatano; Ayataka Fujimoto; Keishiro Sato; Takamichi Yamamoto; Hideo Enoki
Journal:  Brain Sci       Date:  2022-06-11

8.  DNA methylation of the BRD2 promoter is associated with juvenile myoclonic epilepsy in Caucasians.

Authors:  Shilpa Pathak; James Miller; Emily C Morris; William C L Stewart; David A Greenberg
Journal:  Epilepsia       Date:  2018-04-02       Impact factor: 5.864

9.  Aberrant dynamic structure-function relationship of rich-club organization in treatment-naïve newly diagnosed juvenile myoclonic epilepsy.

Authors:  Guangyao Liu; Weihao Zheng; Hong Liu; Man Guo; Laiyang Ma; Wanjun Hu; Ming Ke; Yu Sun; Jing Zhang; Zhe Zhang
Journal:  Hum Brain Mapp       Date:  2022-04-13       Impact factor: 5.399

Review 10.  Seizure-Control Effect of Levatiracetam on Juvenile Myoclonic Epilepsy and Other Epileptic Syndromes: Literature Review of Recent Studies.

Authors:  Arsalan Hashemiaghdam; Amirsina Sharifi; Mojtaba Miri; Abbas Tafakhori
Journal:  Iran J Child Neurol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.